During toxic shock syndrome (TSS), bacterial superantigens trigger a polyclonal T -cell response leading to a potentially catastrophic "cytokine storm". Whether innate-like invariant natural killer T (iNKT) cells, with remarkable immunomodulatory properties, participate in TSS is unclear. Using genetic and cell depletion approaches, we generated iNKT cell-deficient, superantigen-sensitive HLA-DR4-transgenic (DR4tg) mice, which were compared with their iNKT-sufficient counterparts for responsiveness to staphylococcal enterotoxin B (SEB). Both approaches indicate that iNKT cells are pathogenic in TSS. Importantly, treating DR4tg mice with a T H 2-polarizing glycolipid agonist of iNKT cells reduced SEB-inflicted morbidity/mortality. Therefore, iNKT cells may constitute an attractive therapeutic target in superantigen-mediated illnesses.
Staphylococcal enterotoxin B (SEB) and other superantigens (SAgs) secreted by Staphylococcus aureus cause human illnesses ranging from mild food poisoning to potentially fatal toxic shock syndrome (TSS) [1] . Systemic exposure to SAgs results in polyclonal stimulation of T cells irrespective of their cognate specificity. SAgs are inherently capable of binding to select Vβ regions of the T -cell receptor (TCR) and lateral surfaces of major histocompatibility complex (MHC) class II harbored by antigen-presenting cells. Consequently, rapid and massive release of inflammatory mediators is triggered, which can be followed by fever, shock, and organ failure.
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes with profound immunoregulatory properties [2] . Mouse iNKT cells express a canonical TCRα chain with a characteristic Vα14-Jα18 rearrangement, which is paired with one of a limited number of Vβ chains. iNKT cells uniquely recognize glycolipid antigens presented by CD1d.
We previously established that mouse and human iNKT cells can directly respond to group II bacterial SAgs, including SEB, in a CD1d-independent manner [3] . However, whether they play a pathogenic or regulatory role during TSS is unknown. This is an important question in light of the facts that: i) iNKT cells are strategically located at the host-pathogen interface; ii) they exhibit a "preactivated" or "memory-like" phenotype [2] and can, as such, be quickly activated; iii) iNKT cells possess preformed messenger RNA (mRNA) for certain inflammatory cytokines [4] , which enables them to secrete such cytokines amply and speedily; iv) iNKT cells exert pleiotropic effects on numerous downstream effector/regulatory cell types including natural killer (NK), T, B, and dendritic cells, macrophages, and myeloid-derived suppressor cells. Therefore, they shape the nature of ensuing immune responses; and v) iNKT cells are easily "polarizable" towards a pro-or anti-inflammatory phenotype. Therefore, they can be manipulated by synthetic glycolipids in a disease-tailored fashion [5] .
In this work, we have used a humanized mouse model mimicking several aspects of TSS and two distinct experimental strategies, namely genetic deficiency and antibody-mediated depletion of iNKT cells, to determine if: i) iNKT cells are pathogenic effectors of TSS; ii) deviating iNKT cell responses towards a T-helper 2 (T H 2) phenotype ameliorate the severity of TSS.
MATERIALS AND METHODS
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background were bred in our barrier facility. These animals are endogenous MHC class II (IAβ)-deficient but express a chimeric HLA molecule encoded by HLA-DRA-IEα and HLA-DRB1*0401-IEβ transgenes [6] .
To develop an iNKT cell-deficient mouse strain that is humanized to express HLA class II, DR4tg mice were crossed with Jα18 -/-mice, on a C57BL/6 background, which lack iNKT cells [7] . The resultant HLA-DR4tg.Jα18
-/-mice, hereafter referred to as DJ mice, were bred to homozygosity and examined for their expression of HLA-DR transgenes, Jα18 and IAβ, or lack thereof, by polymerase chain reaction (PCR). In brief, ear-clip genomic DNA was prepared using HotSHOT, and PCR was performed using Platinum Taq DNA polymerase (Thermo Fisher). PCR products were visualized by agarose gel electrophoresis. Primers used for genotyping are listed in Supplementary Table 1 .
Wild-type C57BL/6, Jα18
-/-, DR4tg and DJ mice were all housed in the same facility.
Immunophenotyping
Splenic single cell suspensions were prepared in cold, sterile phosphate-buffered saline (PBS) using a Wheaton Dounce tissue grinder. Nonparenchymal hepatic mononuclear cells were isolated by density gradient centrifugation in 33.75% Percoll PLUS (GE Healthcare). For cytofluorimetric analyses, cells were preincubated with 5 μg/mL antimouse CD16/CD32 (clone 2.4G2) before they were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and tetramers (Supplementary Table 2 ). A FACSCanto II cytometer and FlowJo software were used to acquire and analyze data, respectively.
iNKT Cell Depletion DR4tg mice were injected intraperitoneally with 200 μg of an iNKT cell-depleting mAb, NKT14 [8] , which was supplied by NKT Therapeutics Inc. A mouse IgG2a (clone C1.18.4 from BioXCell) was utilized as isotype control. To confirm iNKT cell depletion in NKT14-treated mice, splenic and hepatic mononuclear cells were stained with PBS-57-loaded mouse CD1d tetramer or with empty tetramer (staining control), which were both provided by the National Institutes of Health (NIH) Tetramer Core Facility. An aliquot of the same cell suspensions were subjected, in parallel, to real-time quantitative PCR (qPCR) assaying for the Vα14-Jα18 TCRα gene rearrangement. In brief, RNA was extracted using a PureLink RNA Mini Kit and converted to complementary DNA by SuperScript VILO Master Mix (Thermo Fisher). Contaminating genomic DNA was eliminated using on-column PureLink DNase. PCR was performed using a StepOnePlus System, TaqMan Probes listed in Supplementary Table 1 , and TaqMan Fast Advanced Master Mix (Thermo Fisher). Gene expression fold-changes were calculated by ΔΔC T using TATA-binding protein (TBP) as the reference gene.
TSS Induction and Treatment
Recombinant SEB was cloned from the S. aureus strain COL, expressed in Escherichia coli BL21 (DE3), and purified via nickel column chromatography. Mice were injected intraperitoneally with 100 μg SEB and monitored for up to 7 days, the maximum duration allowed under our protocol. Animals were euthanized when moribund or when 20% weight loss was reached.
Separate cohorts of mice were bled 2, 12, and/or 24 hours after they were injected with SEB or with 4 µg of α-galactosylceramide (αGC) (Funakoshi). Serum cytokine analyses were performed by bead-based multiplexing (Eve Technologies), and the matrix2png utility was employed to generate heat maps.
In several experiments, DR4tg mice were treated intraperitoneally with the T H 2-polarizing iNKT cell agonist OCH (NIH Tetramer Facility) at 4 µg/dose every day beginning 1 day before or 2 hours after SEB injection. Control DR4tg mice received vehicle containing 0.5% Tween-20, 56 mg/mL sucrose and 7.5 mg/mL histidine. Animals were monitored for weight loss and signs of morbidity.
Statistical Analysis
Statistical comparisons were made using Student t test, analysis of variance or log-rank test as appropriate.
RESULTS AND DISCUSSION
We previously demonstrated that bacterial SAgs directly activate iNKT cells [3] . Rieder et al reported that intranasal administration of SEB causes acute lung injury in wild-type mice, but to a lesser degree in Jα18 -/-or CD1d -/-mice [9] . However, intranasal inoculation of SEB does not provoke a cytokine storm [9] among other features of TSS, and the overall in vivo significance of iNKT cells in TSS pathogenesis remains unknown-hence the current investigation.
SAgs display poor affinity for MHC class II molecules expressed in certain conventional mouse strains including C57BL/6 mice [10] , which partially explains why such animals do not provide bona fide models in which to study host responses to SAgs. Therefore, we used DR4tg mice that express a humanized MHC II molecule that can establish interactions of sufficient affinity with SEB [11] . Using this model also eliminates the need for presensitization of mice with commonly used but notoriously toxic agents such as D-galactosamine [12] .
We took two logistically distinct approaches to investigate the role of iNKT cells during TSS in the DR4tg model. First, we crossed DR4tg mice with germ-line iNKT cell knockout mice (Jα18 -/-) to generate an iNKT cell-deficient, SEB-responsive strain. We confirmed that the resulting "DJ" mice express HLA-DR but are devoid of iNKT cells ( Figure 1A ). The frequencies of CD4 + and CD8 + T cells, B cells, dendritic cells, macrophages and NK cells were comparable in DR4tg and DJ mice (Supplementary Figure 1) . When systemically exposed to SEB, DJ mice lost significantly less weight than did iNKT-sufficient DR4tg mice ( Figure 1B) . Strikingly, by (n = 6), Jα18 -/-(n = 6), DR4tg (n = 8) and DJ (n = 8) mice were injected with 100 μg SEB and monitored for weight loss and survival for up to 7 days. Error bars represent the standard error of the mean. *P ≤ 0.05, ***P ≤ 0.001, for statistical differences (two-way analysis of variance; Tukey test) between DR4tg and DJ mice at indicated time points. For survival analyses, mice were euthanized when they reached a weight loss of 20%, and the log-rank test was used for statistical comparisons. C, DR4tg mice were treated with 200 μg of the iNKT cell-depleting mAb NKT14 (n = 12) or an isotype control (n = 15) 24 hours before they were injected with 100 μg SEB. Mice were monitored for up to 7 days and euthanized when moribund as above. The noted P value was calculated using the log-rank test. D, At the endpoint, hepatic and splenic MNCs were isolated and stained with PBS-57-loaded or empty (control) CD1d tetramers and a FITC-conjugated anti-TCRβ mAb. Representative dot plots are illustrated (n = 6/group). In addition, Vα14-Jα18 mRNA levels were quantified by quantitative polymerase chain reaction. Gene expression fold-changes relative to isotype control-treated mice (dotted line) are shown (n = 6/group). *Statistical difference with P ≤ 0.05 (Student t-test; two-tailed) between ΔCT values of NKT14-and isotype control-treated DR4tg mice. (DJ) mice were injected with 100 μg staphylococcal enterotoxin B (SEB) or 4 μg α-galactosylceramide (αGC; control) and bled 2, 12, and 24 hours later. Serum cytokine concentrations were quantified by bead-based multiplexing for DR4tg mice injected with SEB or αGC (n = 6 for each cohort) and for DJ mice injected with SEB (n = 6) or αGC (n = 3). Mean values for each time point were used to generate a heat map (A). In addition, mean ± standard error of the mean (SEM) values (pg/mL) are depicted for the 2-hour time point with *, **, ***, and **** denoting P ≤ 0.05, P ≤ 0.01, P ≤ 0.001, and P ≤ .0001, respectively (Student t-test; two-tailed) (B). C, DR4tg mice (n = 6 per group) were treated daily with OCH (4 μg/dose) or vehicle beginning 1 day before SEB injection. The weight loss percentage (±SEM) is shown for up to 132 hours, after which time high mortality was observed in the vehicle-treated group. *P ≤ 0.05 at indicated individual time points (Student t-test; two-tailed). For survival analysis, mice were sacrificed when moribund (≥20% weight loss), and the P value was calculated by the log-rank test. day 7, 75% of DJ mice had survived, whereas all DR4tg mice succumbed to the SAg challenge ( Figure 1B) . Furthermore, 5 of the 6 surviving DJ mice had either returned to their initial weight or gained weight. SEB-exposed, wild-type C57BL/6 and Jα18 -/-mice showed no signs of morbidity, as expected, due to their lack of humanized MHC II ( Figure 1B) .
The observed differences in morbidity and mortality between DR4tg and DJ mice strongly suggested that iNKT cells are pathogenic in SEB-induced illness. We are cognizant of the recent report that the cellular deficiency found in the original Jα18 -/-mice, which we used to generate DJ mice, is not exclusive to iNKT cells [13] . Therefore, to unequivocally address the role of iNKT cells in TSS, we took advantage of a mAb, clone NKT14, which has become available only recently and which depletes iNKT cells selectively [8] . Pretreatment of DR4tg mice with NKT14 before SEB injection effectively reduced TSS mortality in comparison with DR4tg mice receiving an isotype control reagent ( Figure 1C) , thus recapitulating the DJ phenotype. On day 7 post-SEB insult, 3 out of 4 surviving NKT14-treated mice exhibited moderate weight loss, which was not the basis for their euthanization at the experimental endpoint. To verify iNKT cell depletion by NKT14, livers and spleens were harvested from NKT14-treated and control mice and examined for the absence or presence of iNKT cells. CD1d tetramer staining revealed a near-complete absence of splenic and hepatic iNKT cell detection in NKT14-treated mice ( Figure 1D ). To rule out the possibility that this was due to iNKT cell TCR internalization, as opposed to their depletion, we isolated splenic and hepatic mononuclear cell mRNA from NKT14-treated and control mice and assessed the expression levels of the Vα14-Jα18 TCR gene segment by qPCR. We found the mRNA level corresponding to the Vα14-Jα18 TCRα chain to be dramatically diminished (by ~90%) in the liver of NKT14-treated mice. Interestingly, the mRNA levels in the spleen showed approximately 50% reduction ( Figure 1D ), suggesting that the efficacy of iNKT cell depletion by NKT14 is tissue-specific. This may explain the observed difference in the survival patterns of DJ mice and NKT14-treated DR4tg mice although we find it reassuring that this difference was not statistically significant (Supplementary Figure 2) .
TSS is characterized by a rapid and overwhelming cytokine storm. As iNKT cells are directly activated by SEB [3] and because they can secrete inflammatory cytokines within hours of activation, we hypothesized that they should participate in the cytokine storm, especially in its early wave. Therefore, DR4tg and DJ mice were injected with SEB or with the prototypic iNKT cell superagonist αGC (positive control), and serum cytokine levels were measured 2, 12, and 24 hours later. Consistent with our hypothesis, the majority of cytokines and chemokines induced by SEB in DR4tg mice reached their peak at the earliest time point examined (i.e., at 2 hours) (Figure 2A ).
In fact, several proinflammatory cytokines including interleukin (IL)-1α, IL-6, IL-17A and tumor necrosis factor (TNF)-α were only present at the 2-hour time point (Figure 2A and Supplementary Figure 3) , suggesting that this early wave of cytokines may initiate or at least contribute to the TSS inflammatory cascade. Importantly, when compared to DR4tg mice, SEB-exposed DJ mice showed reduced levels of several cytokines known to play a direct role in TSS immunopathology, namely IL-1α, IL-2, IL-6, and TNF-α ( Figure 2B ). Multiple chemokines (CCL1, CCL4, CCL5, CXCL1, and CXCL10) and growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor) were also decreased in DJ mice ( Figure 2B ). Together, these results implicate iNKT cells in production of inflammatory mediators early in the course of TSS and suggest that the observed reduction in morbidity and mortality of DJ mice may be owed to an attenuated cytokine storm.
Because the role of iNKT cells in TSS was generally proinflammatory, we attempted to skew their responses toward an anti-inflammatory phenotype using a T H 2-polarizing αGC analogue called OCH [14] . DR4tg mice were administered OCH or vehicle daily before and after receiving SEB. OCH pretreatment markedly reduced weight loss and rescued approximately 85% of the animals ( Figure 2C ). Mechanistically, this finding indicates that it is indeed the proinflammatory capacity of iNKT cells that promotes TSS pathogenesis. To simulate clinical scenarios in which treatments are given after the TSS onset, we started OCH treatment in a separate cohort of DR4tg mice 2 hours after the SEB insult, which coincides with the peak of several inflammatory cytokines (Figure 2A and 2B) . Therapeutic administration of OCH inhibited SEB-induced weight loss and mortality (Supplementary Figure 4) .
Our findings are likely translatable to clinical settings because: i) iNKT cells' mode of glycolipid antigen surveillance is evolutionarily conserved [15] ; and ii) glycolipid agonists of iNKT cells have shown promise in clinical trials for conditions other than TSS [5] . Unlike conventional T cells that are restricted by highly polymorphic MHC molecules, iNKT cells respond to glycolipid antigens presented by the monomorphic CD1d. Therefore, CD1d-restricted glycolipids can be used in diverse human populations. iNKT cells likely represent only one of several early mediators of TSS. Nevertheless, tangible clinical benefits may arise from iNKT cell-based therapies, alone or in combination with other modalities, for TSS.
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